RxDoctor Payments DataLook up a doctor →

Clifton Nicholson-Uhl, MD

Obstetrics & Gynecology · Marrero, LANPI 1184706913

Payments from drug & device makers

$1,685,351in general payments, 2019–2025

Across 669 payments — averaging $2519.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biontech SE$384K
  • Sumitomo Pharma America, Inc.$360K
  • Mylan Inc.$235K
  • AbbVie$178K
  • Mylan Technologies Inc.$177K
  • Sebela Pharmaceuticals Inc.$88K
  • plus $263K from 34 others

What the payments were for

  • Food & beverage$2,77597%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,685,351 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$5,852
Medicare patients
68
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$29,719
ProliaDenosumab16$26,437
PremarinEstrogens, Conjugated28$8,184
Estradiol89$4,604
Raloxifene Hcl44$1,843
Fesoterodine Fumarate ErFesoterodine Fumarate11$950
ValacyclovirValacyclovir Hcl41$699
YuvafemEstradiol11$633
Clobetasol Propionate19$385
Microgestin FeNorethindrone-E.Estradiol-Iron13$342
Metronidazole11$309
Tolterodine Tartrate ErTolterodine Tartrate12$260
Oxybutynin Chloride ErOxybutynin Chloride15$190
Escitalopram Oxalate11$110
Paroxetine Hcl18$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$178,050$29,71926 claims
AmgenProlia$26$26,43716 claims
PfizerPremarin$237$8,18428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →